Antonio Calles, Head of the Lung Cancer Unit at Hospital Ruber Internacional, shared a post on X:
“ASTRUM-002 phase Ill study Serplulimab plus chemotherapy with or without HLXO4 (bevacizumab biosimilar) in advanced nonsquamous NSCLC.
While serplulimab improved both PFS and OS, bevacizumab biosimilar did not have additive efficacy with serplulimab. Control arm based on chemo only is no longer the standard of care.”
You Can Also Read:
ESMO 2025 Day 1 Highlights Not to Miss
ESMO 2025 Day 2 Highlights Not to Miss
ESMO 2025 Day 3 Highlights Not to Miss
